D-Amino acid oxidase (DAO) has been established to be involved in the oxidation of D-serine, an allosteric activator of the N-methyl-D-aspartate-type glutamate receptor in the brain, and to be associated with the onset of schizophrenia. The effect of risperidone, a benzisoxazole derivative, atypical antischizophrenic drug, on the activity of human DAO was tested using an in-vitro oxygraph system and rat C6, stable C6 transformant cells overexpressing mouse DAO (designated as C6/DAO) and pig kidney epithelial cells (LLC-PK1). Risperidone has a hyperbolic mixed-type inhibition, designated as ‘partial uncompetitive inhibition effect’, with Ki value of 41 μM on human DAO. Risperidone exhibited a protective effect from D-amino acid induced cell death in both C6/DAO and LLC-PK1 cells with 10% increase in viability. These data indicate the involvement of DAO activity in D-serine metabolism and also suggest a new mechanism of action to risperidone as antischizophrenic drug.
Aravagiri, M., Marder, SR ( 2002) Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl) 159: 424-431.
2.
Baldessarini, RJ, Centorrino, F., Flood, JG, Volpicelli, SA, Huston-Lyons, D., Cohen, BM ( 1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology9: 117-124.
3.
Biber, J., Brown, CD, Murer, H. ( 1983) Sodium-dependent transport of phosphate in LLC-PKI cells . Biochim Biophys Acta735: 325-330.
4.
Carman, J., Peuskens, J., Vangeneugden, A. ( 1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol10: 207-213.
5.
Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., et al. (2002) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia . Proc Natl Acad Sci U S A99: 13365-13367.
6.
Contreras, PC ( 1990) D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology29: 291-293.
7.
Cunningham, TJ, Maciejewski, J., Yao, L. ( 2006) Inhibition of secreted phospholipase A2 by neuron survival and anti-inflammatory peptide CHEC-9. J Neuroinflammation3: 25.
8.
Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., et al. (2007) Efficacy, safety and early response of paliperidone extendedrelease tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr Res93: 117-130.
9.
DeVane, CL, Markowitz, JS ( 2000) Drugs as substrates of metabolic enzymes: antipsychotics . In: Levy, RH, Thummel, KE, Trager, WF, Hansten, PD, Eichelbaum, M, (eds), Metabolic Drug Interactions. Philadelphia, PA: Lippincott-Raven Press , pp. 245-258.
10.
Dixon, M., Webb, EC, Thorne, CJR, Tipton, KF ( 1964) Enzymes. London: Lomgman, pp. 343-345.
11.
Fang, J., Borurin, M., Baker, GB ( 1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol359: 147-151.
12.
Fenton, WS, Blyler, CR, Heinssen, RK ( 1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull23: 637-651.
13.
Fishman, WH ( 1989) On the importance of being (stereo) specific. Clin Chim Acta186: 129-132.
14.
Fukui, K., Miyake, Y. ( 1992) Molecular cloning and chromosomal localization of a human gene encoding D-amino acid oxidase. J Biol Chem267: 18631-18638.
15.
Fukui, K., Momoi, K., Watanabe, F., Miyake, Y. ( 1988) In vivo and in vitro expression of porcine D-amino acid oxidase: In vitro system for the synthesis of a functional enzyme. Biochemistry27: 6693- 6697.
16.
Fukui, K., Watanabe, F., Shibata, T., Miyake, Y. ( 1987) Molecular cloning and sequence analysis of cDNAs encoding porcine kidney D-amino acid oxidase. Biochemistry26: 3612-3618.
17.
Ganote, CE, Peterson, DR, Carone, FA ( 1974) The nature of D-serine induced nephrotoxicity. Am J Pathol77: 269-282.
18.
Gilbert, SF, Migeon, BR ( 1975) D-valine as a selective agent for normal human and rodent epithelial cells in culture. Cell5: 11-17.
19.
Goff, DC, Tsai, G., Levitt, J., Hayden, DL, McCarley, R., Coyle, JT ( 1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiat56: 21-27.
Gstraunthaler, G., Pfaller, W., Kotanko, P. ( 1985) Biochemical characterization of renal epithelial cell cultures (LLC-PK1 and MDCK). Am J Physiol248(4 pt2): F536-F544.
22.
Hashimoto, K., Fukushimo, T., Shinizu, E., Komatsu, N., Watanabe, H., Shinoda, N., et al. (2003) Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry60: 572-576.
23.
Hashimoto, A., Nishikawa, T., Hayashi, T., Fujii, N., Harada, K., Oka, T., et al. (1992) The presence of free D-serine in rat brain . FEBS Lett296: 33-36.
24.
Hashimoto, A., Nishikawa, T., Oka, T., Takahashi, K. ( 1993) Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J Neurochem60: 783-786.
25.
Hashimoto, A., Oka, T., Nishikawa, T. ( 1995) Extracellular concentration of endogenous free D-serine in the rat brain as revealed by in vivo microdialysis. Neuroscience66: 635-643.
26.
Hashimoto, A., Oka, T. ( 1997) Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol52: 325-353.
27.
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., Javitt, DC ( 2004) High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry55: 165-171.
28.
Heresco-Levy, U., Javitt, DC, Ermilov, M., Mordel, C., Silipo, G., Lichtenstein, M. ( 1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry56: 29-36.
29.
Heresco-Levy, U., Javitt, DC, Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., et al. (2005) D-Serine Efficacy as Add-on Pharmacotherapy to Risperidone and Olanzapine for Treatment-Refractory Schizophrenia. Biol Psychiatry57: 577-585.
30.
Heykants, J., Huang, ML, Mannens, G., Meuldermans, W., Snoeck, E., Van Beijsterveldt, L., et al. (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry55: 13-17.
31.
Huang, CL ( 1967) Isolation and identification of urinary chlorpromazine metabolites in man. Int J Neuropharmacol6: 1-13.
32.
Hull, RN, Cherry, WR, Weaver, GW ( 1976) The origin and characteristics of a pig kidney cell strain, LLC-PK1. In Vitro12: 670-677.
33.
Iwana, S., Kawazoe, T., Park, HK, Tsuchiya, K., Ono, K., Yorita, K., et al. (2008) Chlorpromazine oligomer is a potentially active substance that inhibits human D-amino acid oxidase, product of a susceptibility gene for schizophrenia. J Enzyme Inhib Med Chem23: 901-911.
34.
Kawazoe, T., Tsuge, H., Pilone, MS, Fukui, K. ( 2006) Crystal structure of human D-amino acid oxidase: Context-dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si-face of the flavin ring. Protein Sci15: 2708-2717.
35.
Marder, SR, Meibach, RC ( 1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry151: 825-835.
36.
Massey, V., Curti, B. ( 1966) A new method of preparation of D-amino acid oxidase apoprotein and a conformational change after its combination with flavin adenine dinucleotide . J Biol Chem241: 3417- 3423.
37.
Misfeldt, DS, Sanders, MJ ( 1981) Transepithelial transport in cell culture: D-glucose transport by a pig kidney cell line (LLCPKI). J Membr Biol59: 13-18.
38.
Möller, HJ ( 1999) Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci249(Suppl 4): 99-107.
39.
Möller, HJ ( 2003) Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs17: 793-823.
40.
Momoi, K., Fukui, K., Watanabe, F., Miyake, Y. ( 1988) Molecular cloning and sequence analysis of cDNA encoding human kidney D-amino acid oxidase. FEBS Lett238: 180-184.
41.
Mothet, JP, Parent, AT, Wolosker, H., Brady Jr., RO, Linden, DJ, Ferris, CD, et al. (2000) D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A97: 4926-4931.
42.
Nasrallah, HA, Mulvihill, T. ( 2001) Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry13: 215-227.
43.
Ohama, H., Sugiura, N., Tanaka, F., Yagi, K. ( 1977) Effect of alcohols on the structure and function of D-amino-acid oxidase. Biochemistry16: 126-131.
44.
Park, HK, Shishido, Y., Ichise-Shishido, S., Kawazoe, T., Ono, K., Iwana, S., et al. (2006) Potential role for astroglial D-amino acid oxidase in extracellular D-serine metabolism and cytotoxicity. J Biochem139: 295-304.
45.
Perantoni, A., Berman, JJ ( 1979) Properties of Wilms’ tumor line (TuWi) and pig kidney line (LLC-PKI) typical of normal kidney tubular epithelium. In Vitro15: 446-454.
46.
Pfaller, W., Gstraunthaler, G., Loidl, P. ( 1990) Morphology of the Differentiation and Maturation of LLC-PK1Epithelia . J Cell Physiol142: 247-254.
47.
Pilone, MS ( 2000) D-Amino acid oxidase: new findings. Cell Mol Life Sci57: 1732-1747.
48.
Prior, TI, Baker, GB ( 2003) Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci28: 99-112.
49.
Rabito, CA ( 1981) Localization of the Na+-sugar cotransport system in a kidney epithelial cell line (LLC-PKI). Biochim Biophys Acta649: 286-296.
50.
Rabito, CA ( 1983) Phosphate uptake by a kidney cell line (LLC-PK1) . Am J Physiol245: F22-F31.
51.
Rabito, CA, Ausiello, DA ( 1980) Na+-dependent sugar transport in a cultured epithelial cell line from pig kidney. J Membr Biol54: 31-38.
52.
Rabito, CA, Karish, MV ( 1982) Polarized amino acid transport by an epithelial cell of renal origin (LLC-PK1): the basolateral systems. J Biol Chem257: 6802-6808.
53.
Rabito, CA, Karish, MV ( 1983) Polarized amino acid transport by an epithelial cell line of renal origin (LLC-PK1): the apical systems. J Biol Chem258: 2543-2547.
54.
Rabito, CA, Kreisberg, JI, Wight, D. ( 1984) Alkaline phosphatase and -γ-glutamyltranspeptidase as polarization markers during the organization of LLC- PK1 cells into an epithelial membrane. J Biol Chem259: 574-582.
55.
Salzer, JL, Lovejoy, L., Liner, MC, Rosen, C. ( 1998) Ran-2, a glial lineage marker, is a GPI-anchored form of ceruloplasmin. J Neurosci Res54: 147-157.
56.
Schell, MJ, Molliver, ME, Snyder, SH ( 1995) D-Serine an endogenous synaptic modulator: localization to astrocytes and glutamatestimulated release. Proc Natl Acad Sci U S A92: 3948-3952.
57.
Schotte, A., Janssen, PF, Gommeren, W., Luyten, WH, Van Gompel, P., Lesage, AS, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berlin) 124: 57-73.
58.
Schotte, A., Janssen, PF, Megens, AA, Leysen, JE ( 1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography . Brain Res631: 191-202.
59.
Scordo, MG, Spina, E., Facciolà, G., Avenoso, A., Johannsson, I., Dahl, ML ( 1999) Cytochcorome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 147: 300-305.
60.
Seeman, P. ( 2005) An update of fast-off dopamine D2 atypical antipsychotics . Am J Psychiatry162: 1984-1985.
61.
Segel, IH ( 1993) Enzyme Kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme system. California : John Wiley & Sons, Inc. pp. 189-192.
62.
Sepúlveda, FV, Burton, KA, Pearson, JD ( 1982) The development of gamma- glutamyltransferase in a pig renal-epithelial-cell line in vitro relationship to amino acid transport . Biochem J208: 509-512.
63.
Sepúlveda, FV, Pearson, JD ( 1982) Characterization of neutral amino acid uptake by cultured epithelial cells from pig kidney. J Cell Physiol112: 182-188.
64.
Snyder, SH ( 2002) Forty years of neurotransmitters: A personal account . Arch Gen Psychiatry59: 983-994.
65.
Tanii, Y., Nishikawa, T., Hashimoto, A., Takahashi, K. ( 1994) Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther269: 1040-1048.
66.
Tomar, RS, Joseph, TJ, Murthy, AS, Yadav, DV, Subbaiah, G., Krishna Reddy, KV ( 2004) Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms. J Pharm Biomed Anal36: 231-235.
67.
Tsai, G., Yang, P., Chung, L-C., Lange, N., Coyle, JT ( 1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry44: 1081-1089.
68.
Tsai, GE, Yang, P., Chung, LC, Tsai, IC, Tsai, CW, Coyle, JT ( 1999) D-serine added to clozapine for the treatment of schizophrenia . Am J Psychiatry156: 1822-1825.
69.
Urai, Y., Jinnouchi, O., Kwak, KT, Suzue, A., Nagahiro, S., Fukui, K. ( 2002) Gene expression of D-amino acid oxidase in cultured rat astrocytcs: Regional and cell type specific expression. Neurosci Lett324: 101-104.
70.
Van Beijsterveldt, LE, Geerts, RJ, Leysen, JE, Megens, AA, Van den Eynde, HM, Meuldermans, WE, et al. (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat. Psychopharmacology114: 53-62.
71.
Yagi, K., Nagatsu, T., Ozawa, T. ( 1956) Inhibitory action of chlorpromazine on the oxidation of D-amino-acid in the diencephalon part of the brain. Nature177: 891-892.
72.
Yagi, K., Ozawa, T., Nagatsu, T. ( 1960) Mechanism of inhibition of D-amino acid oxidase. IV. Inhibitory action of chlorpromazine. Biochim Biophys Acta43: 310-317.
73.
Wiles, DH, Orr, MW, Kolakowska, T. ( 1978) Chlorpromazine levels in plasma and milk of nursing mothers . Br J Clin Pharmacol5: 272-273.
